Genomic Valley Biotech MD, chairman, board of directors and AGM
BSE: 539206Pharmaceuticals & BiotechnologySmall Cap
Share price at the BSE close on 23 Oct 2026. Previous close ₹35.92.
- Under BSE's graded surveillance, stage 0, on the list for 22 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Next results date: the board meets on 30 Oct 2026 to consider: quarterly results.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹12 Cr4,774th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 15 Aug 2026
- 567.4
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 30 May 2026
- 2.9
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 15 Aug 2026
- 0.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 15 Aug 2026
- 0.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 30 May 2026
- 0.00
- Volume, BSEVolume. Shares traded on the last trading day.
- 2,994
Genomic Valley Biotech board of directors
At the end of the quarter to Dec 2023, as the company filed it; changes since are in its announcements.Their trades in its shares
- ChairpersonYOGESH AGRAWALRelated to the promoter
- Company Secretary and Compliance OfficerAnupam Aditya
5 directors2 independent1 executive2 non-executive
- YOGESH AGRAWAL · ChairpersonExecutive · joined Sep 2015 · reappointed Sep 2020 · 1 listed board
- PARUL AGRAWALNon-executive · joined Sep 2010 · 0 listed boards
- Praveen Kumar MishraIndependent · joined Jun 2023 · reappointed Jun 2023 · 6 months as independent · 1 listed board · 1 as independent · 2 committee seats, 2 as chair
- Jyoti BansalIndependent · joined Jun 2023 · reappointed Jun 2023 · 5 months as independent · 2 listed boards · 2 as independent · 4 committee seats, 1 as chair
- Ashok KumarNon-executive · joined Nov 2023 · reappointed Nov 2023 · 1 listed board · 2 committee seats
An independent director has no business or family tie to the company, its promoters or its managers beyond the seat. Listed boards counts the boards of listed companies the director sits on, this one included, and "as independent" how many of those seats are independent ones. Committee seats are audit and stakeholder committee seats across those companies. Months as independent is filed for independent directors only, whose terms the rules cap. Disqualified is the company's own mark that a director may not serve under company law.
Committees and meetings
Who sits on each, and how often they met.Board meeting notices and outcomes
Board
- 14 Nov 20234 of 4 present2 independent · 70 days in between
- 4 Sep 20234 of 4 present2 independent · 20 days in between
- 14 Aug 20234 of 4 present2 independent
Audit Committee
Chair Praveen Kumar Mishra
PARUL AGRAWAL, Jyoti Bansal, Ashok Kumar
- 14 Nov 20233 of 3 present2 independent · 70 days in between
- 4 Sep 20233 of 3 present2 independent · 20 days in between
- 14 Aug 20233 of 3 present2 independent
Nomination and remuneration committee
Chair Praveen Kumar Mishra
PARUL AGRAWAL, Jyoti Bansal, Ashok Kumar
- 14 Nov 20233 of 3 present2 independent · 70 days in between
- 4 Sep 20233 of 3 present2 independent · 20 days in between
- 14 Aug 20233 of 3 present2 independent
Stakeholders Relationship Committee
Chair Praveen Kumar Mishra
PARUL AGRAWAL, Jyoti Bansal, Ashok Kumar
- 14 Nov 20233 of 3 present2 independent
Risk Management Committee
Chair Praveen Kumar Mishra
PARUL AGRAWAL, Jyoti Bansal, Ashok Kumar
No meeting listed in the filing.
Meetings in the quarter filed and the one before it. The days in between are as the company files them, neither meeting's day counted; the rules allow at most 120. A quorum is the least number of members who must attend for the meeting to decide anything.
Statutory auditor
Named in the results for the quarter to Mar 2026.
- ANDROS & CO.Peer-review certificate valid to Dec 2027
A statutory auditor checks the company's accounts and signs its results. Peer review is the accountants' institute's check of an audit firm's own work, which a listed company's auditor must hold a valid certificate of.
Compliance
- The board is made up as the listing rules require
- Yes
- The board has a regular chairperson
- Yes
- The company has a risk management committee
- No
- The chair is related to the managing director
- Yes
The company's own answers in its filing.